概括
早期诊断莱维体痴呆症 (DLB) 和其前兆期对于预防并发症和及时干预至关重要. 生物标志物的进步有助于识别患有这种复杂的神经退行性疾病的风险.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 老年病的医生 老年病的医生
背景情况:
- 勒维体痴呆症 (DLB) 是一种复杂的神经退行性疾病.
- DLB经常与其他痴呆症重叠症状,使诊断复杂化.
- 副病理学,特别是阿尔茨海默病,加剧了认知衰退和死亡风险.
研究的目的:
- 审查勒维体痴呆症 (DLB) 的诊断标准.
- 讨论DLB的前期阶段,以便更早地识别风险.
- 概述DLB目前的管理策略.
主要方法:
- 对DLB及其前兆综合征的诊断标准的审查.
- 对DLB生物标志物开发的最新进展进行分析.
- 讨论DLB管理的跨学科方法.
主要成果:
- 预发性DLB的诊断标准可以更早地识别有风险的个体.
- 生物标志物的进步包括化α-synuclein检测和CSFα-synuclein种子放大试验.
- 优化诊断和管理需要一个跨学科的方法,考虑频繁的共病理.
结论:
- 早些时候识别DLB及其预发性阶段可以预防阳性并发症.
- 生物标志物对于指导DLB的准确诊断和管理至关重要.
- 综合方法对于管理DLB的复杂性及其对患者和家人的影响至关重要.
相关概念视频
Dementia
166
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
166
Parkinson's Disease: Overview
710
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
710
Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
Neural Regulation
40.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.1K
Lysosomal Hydrolases
3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262


